Tianjin Ringpu Bio Tech (SHE:300119) — Market Cap & Net Worth
Market Cap & Net Worth: Tianjin Ringpu Bio Tech (300119)
Tianjin Ringpu Bio Tech (SHE:300119) has a market capitalization of $1.17 Billion (CN¥8.00 Billion) as of August 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #8135 globally and #1842 in its home market, demonstrating a 10.88% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tianjin Ringpu Bio Tech's stock price CN¥17.22 by its total outstanding shares 464754706 (464.75 Million). See Tianjin Ringpu Bio Tech (300119) reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Tianjin Ringpu Bio Tech Market Cap History: 2015 to 2026
Tianjin Ringpu Bio Tech's market capitalization history from 2015 to 2026. Data shows growth from $1.20 Billion to $1.17 Billion (2.59% CAGR).
Tianjin Ringpu Bio Tech Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tianjin Ringpu Bio Tech's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.38x
Tianjin Ringpu Bio Tech's market cap is 0.38 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.19x
Tianjin Ringpu Bio Tech's market cap is 3.19 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.03 Billion | $969.86 Million | $132.78 Million | 1.06x | 7.77x |
| 2017 | $723.76 Million | $1.05 Billion | $104.90 Million | 0.69x | 6.90x |
| 2018 | $461.60 Million | $1.19 Billion | $118.98 Million | 0.39x | 3.88x |
| 2019 | $898.06 Million | $1.47 Billion | $194.36 Million | 0.61x | 4.62x |
| 2020 | $1.19 Billion | $2.00 Billion | $398.20 Million | 0.59x | 2.99x |
| 2021 | $1.54 Billion | $2.01 Billion | $412.78 Million | 0.77x | 3.73x |
| 2022 | $1.21 Billion | $2.08 Billion | $346.70 Million | 0.58x | 3.50x |
| 2023 | $1.09 Billion | $2.71 Billion | $453.59 Million | 0.40x | 2.40x |
| 2024 | $1.25 Billion | $3.07 Billion | $300.72 Million | 0.41x | 4.15x |
| 2025 | $1.28 Billion | $3.40 Billion | $400.51 Million | 0.38x | 3.19x |
Competitor Companies of 300119 by Market Capitalization
Companies near Tianjin Ringpu Bio Tech in the global market cap rankings as of August 5, 2026.
Key companies related to Tianjin Ringpu Bio Tech by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #504 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #543 globally with a market cap of $49.47 Billion USD ( CN¥338.09 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #549 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #504 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #543 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $49.47 Billion | CN¥53.00 |
| #549 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.97 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.70 |
Tianjin Ringpu Bio Tech Historical Marketcap From 2015 to 2026
Between 2015 and today, Tianjin Ringpu Bio Tech's market cap moved from $1.20 Billion to $ 1.17 Billion, with a yearly change of 2.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.17 Billion | -8.26% |
| 2025 | CN¥1.28 Billion | +2.18% |
| 2024 | CN¥1.25 Billion | +14.77% |
| 2023 | CN¥1.09 Billion | -10.40% |
| 2022 | CN¥1.21 Billion | -21.18% |
| 2021 | CN¥1.54 Billion | +29.63% |
| 2020 | CN¥1.19 Billion | +32.41% |
| 2019 | CN¥898.06 Million | +94.55% |
| 2018 | CN¥461.60 Million | -36.22% |
| 2017 | CN¥723.76 Million | -29.85% |
| 2016 | CN¥1.03 Billion | -13.66% |
| 2015 | CN¥1.20 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Tianjin Ringpu Bio Tech was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.17 Billion USD |
| MoneyControl | $1.17 Billion USD |
| MarketWatch | $1.17 Billion USD |
| marketcap.company | $1.17 Billion USD |
| Reuters | $1.17 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tianjin Ringpu Bio Tech
Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sale of veterinary raw materials, pharmaceutical preparation, functional additives, and veterinary biological products. The company provides vaccines, chemical drugs, traditional Chinese medicines; feed additives, including pigs, chickens, waterfowl, cattle, sheep and pet medicines, and vaccines; and p… Read more